ProPhotonix Announces New Restricted Line Stock

SALEM, NH—(Marketwired – Aug 17, 2017) – ProPhotonix Limited (OTC PINK: STKR) (LSE: PPIX) (AIM: PPIX)

OTC: STKR and London Stock Exchange – AIM: PPIX

ProPhotonix Announces New Restricted Line Stock

(Salem, New Hampshire, August 17, 2017) ProPhotonix Limited (OTC: STKR and London Stock Exchange – AIM: PPIX), a high technology designer and manufacturer of LED illumination systems and laser diode modules, with operations in Ireland and the United Kingdom, announces that 22,042,143 of the Company's existing common shares of $0.001 each (“Common Shares”), trading under the Company's existing ISIN (US7434651060) are being transferred with effect from August 18, 2017 to a new restricted line of common shares, represented by a new ISIN (USU743121142) and new ticker (AIM: PPIR) (“Restricted Line Stock”).

Application has been made for the Restricted Line Stock to be admitted to trading on AIM (“Admission”) and it is expected that Admission will become effective and that dealings in the Restricted Line Stock will commence at 8.00 a.m. on August 18, 2017. The Restricted Line Stock will be identical in all respects with the Common Shares trading on the Company's existing ISIN save that the Restricted Line Stock will be subject to the conditions listed under section 903(b)(3), or Category 3, of Regulation S (“Regulation S”) promulgated under the US Securities Act 1933 (“Securities Act”).

Upon Admission, the Restricted Line Stock (as represented by Depository Interests) may be held in the CREST system and will be segregated into a separate trading system within CREST identified with the marker “REG S” and ISIN USU743121142.

Following Admission, the total issued share capital of the Company will remain unchanged at 90,825,402 Common Shares. There are no Common Shares held in treasury. Therefore, the total number of voting rights in the Company will be 90,825,402. Shareholders in the Company may use this figure as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company.

Important Notice
Each purchaser of the Restricted Line Stock (“Purchaser”) agrees to reoffer or resell the Restricted Line Stock only pursuant to registration under the Securities Act or in accordance with the provisions of Regulation S or pursuant to another available exemption from registration, and agrees not to engage in hedging transactions with regard to such securities unless in compliance with the Securities Act. The restrictions restrict purchasers of the Restricted Line Stock from reselling the Restricted Line Stock in the United States or to a US Person. These restrictions may remain in place or be reintroduced following the expiry of one year following Admission in relation to the Restricted Line Stock at the discretion of the Company.

The Restricted Line Stock to be admitted to trading on AIM and held in the CREST system as Depositary Interests will be identified with the marker “REGS” and will be segregated into a separate trading system within CREST. The “REGS” marker also indicates that the Restricted Line Stock held in the CREST system will also bear a legend setting out certain transfer restrictions and other information, including that: (i) transfers of the Restricted Line Stock are prohibited except in accordance with the provisions of Regulation S, pursuant to registration under the Securities Act or in a transaction not subject to the registration requirements of the Securities Act; and (ii) hedging transactions involving the Restricted Line Stock may not be conducted unless in compliance with the Securities Act.

Representations, warranties and certifications must be made through the CREST system by those selling or acquiring the Restricted Line Stock. If such representations, warranties and certifications cannot be made or are not made, settlement through CREST will be rejected. Furthermore, any Restricted Line Stock held by “Affiliates” (as defined in Rule 405 of the Securities Act) of the Company shall be held in certificated form and accordingly settlement shall not be permitted via CREST until such time as the relevant restrictions are no longer applicable. Affiliates of the Company at the time of Admission (or at any time during the 90 days immediately before Admission), or investors that become Affiliates at any time after Admission, should seek independent US legal counsel prior to selling or transferring any Restricted Line Stock.

THE RESTRICTED LINE STOCK HAS NOT BEEN, AND IS NOT EXPECTED TO BE, REGISTERED UNDER THE APPLICABLE SECURITIES LAWS OF JAPAN, ANY PROVINCE OF CANADA, AUSTRALIA, THE REPUBLIC OF SOUTH AFRICA OR IN ANY OTHER JURISDICTION WHERE THIS WOULD CONSTITUTE A BREACH OF APPLICABLE SECURITIES LEGISLATION. ACCORDINGLY, SUBJECT TO CERTAIN EXCEPTIONS, THE RESTRICTED LINE STOCK MAY NOT, DIRECTLY OR INDIRECTLY, BE OFFERED OR SOLD WITHIN JAPAN, ANY PROVINCE OF CANADA, AUSTRALIA, THE REPUBLIC OF SOUTH AFRICA OR A NATIONAL, CITIZEN OR RESIDENT OF JAPAN, ANY PROVINCE OF CANADA, AUSTRALIA OR REPUBLIC OF SOUTH AFRICA.

FURTHERMORE, THE RESTRICTED LINE STOCK HAS NOT BEEN AND WILL NOT BE REGISTERED UNDER THE SECURITIES ACT, OR THE SECURITIES LAWS OF ANY STATE OF THE UNITED STATES OF AMERICA, AND MAY NOT BE OFFERED OR SOLD IN THE UNITED STATES OF AMERICA, OR TO OR FOR THE ACCOUNT OR BENEFIT OF US PERSONS (AS DEFINED IN REGULATION S UNDER THE SECURITIES ACT), ABSENT REGISTRATION UNDER THE SECURITIES ACT OR PURSUANT TO AN EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT. THE RESTRICTED LINE STOCK MAY BE OFFERED AND SOLD ONLY OUTSIDE THE UNITED STATES OF AMERICA TO NON–US PERSONS IN ''OFFSHORE TRANSACTIONS'' (AS DEFINED IN REGULATION S UNDER THE SECURITIES ACT) IN ACCORDANCE WITH AND IN RELIANCE ON THE SAFE HARBOUR FROM REGISTRATION PROVIDED BY SECTION 903(B)(3), OR CATEGORY 3, OF REGULATION S UNDER THE SECURITIES ACT.

This Announcement does not constitute a prospectus or offering memorandum or an offer in respect of any securities and is not intended to provide the basis for any decision in respect of the Company or other evaluation of any securities of the Company or any other entity and should not be considered as a recommendation that any investor should subscribe for or purchase any such securities.

This Announcement or any part of it does not constitute or form part of any offer to issue or sell, or the solicitation of an offer to acquire, purchase or subscribe for, any securities in the United States, Japan, any province of Canada, Australia, the Republic of South Africa or any other jurisdiction in which the same would be unlawful. No public offering of the Restricted Line Stock is being made in any such jurisdiction.

Inquiries/Contacts
ProPhotonix Limited
Tim Losik, President and CEO 
Tel: +1 603 893 8778
ir@prophotonix.com

Stockdale Securities Limited
Tom Griffiths / David Coaten 
Tel: +44 (0) 20 7601 6100
Nominated Adviser and Broker

About ProPhotonix
ProPhotonix Limited, headquartered in Salem, New Hampshire, is a high technology designer and manufacturer of LED illumination systems and laser diode modules for industry leading OEMs and medical equipment companies. In addition, the Company distributes premium diodes for Ushio (formerly OCLARO), Osram, QSI, Panasonic, and Sony. The Company serves a wide range of markets including the machine vision, industrial inspection, security, and medical markets. ProPhotonix has offices and subsidiaries in the U.S., Ireland, U.K., and Europe. For more information about ProPhotonix and its innovative products, visit the Company's web site at www.prophotonix.com.

This information is provided by RNS
The company news service from the London Stock Exchange

American Hotel Income Properties REIT LP Announces August 2017 U.S. Dollar Cash Distribution

VANCOUVER, BC—(Marketwired – August 17, 2017) – American Hotel Income Properties REIT LP (“AHIP“) (TSX: HOT.UN) (TSX: HOT.DB.U) (OTCQX: AHOTF) announced today a cash distribution of US$0.054 per limited partnership unit (“Unit“) for the period of August 1, 2017 to August 31, 2017, which is equivalent to US$0.648 per Unit on an annualized basis. The distribution will be paid on September 15, 2017 to unitholders of record at the close of business on August 31, 2017.

The policy of AHIP is to pay cash distributions on or about the 15th day of each month to the unitholders of record on the last business day of the preceding month.

ABOUT AMERICAN HOTEL INCOME PROPERTIES REIT LP

AHIP is a limited partnership formed under the Limited Partnerships Act (Ontario) to invest in hotel real estate properties located substantially in the United States and engaged primarily in growing a portfolio of premium branded, select–service hotels in secondary markets with diverse and stable demand generators as well as long standing contractual railway customers.

AHIP's long–term objectives are to build on its proven track record of successful investment, deliver reliable and consistent U.S. dollar denominated distributions to unitholders and add value through ongoing growth of its diversified hotel portfolio.

ADDITIONAL INFORMATION

Additional information relating to AHIP, including its other public filings, is available on SEDAR at www.sedar.com and on AHIP's website at www.ahipreit.com.

THE TORONTO STOCK EXCHANGE HAS NOT REVIEWED AND DOES NOT ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR THE ACCURACY OF THIS NEWS RELEASE.

Batero Gold Announces Grant of Options

VANCOUVER, BC—(Marketwired – August 16, 2017) – Batero Gold Corp. (“Batero,” the “Company“) (TSX VENTURE: BAT) (FRANKFURT: 68B) (OTC PINK: BELDF) is pleased to announce the grant of 1,500,000 stock options (“Options“) to purchase common shares (“Shares“) to Gonzalo de Losada, President and CEO of Batero. All of the Options granted will vest immediately and have an exercise price of $0.20 per Share for a term of up to 5:00 p.m. Vancouver Time on the 15th day of August, 2022. The Options will expire 90 days after Mr. de Losada ceases to be employed by, or provide services to, the Company.

The Company announces that Mr. Alvaro Espinoza has resigned as Executive Vice President of the Company. The Company would like to thank Mr. Espinoza for his dedication, hard work and support.

ON BEHALF OF THE BOARD OF BATERO GOLD CORP.

Gonzalo de Losada
President and CEO
Batero Gold Corporation

ABOUT BATERO GOLD

Batero Gold Corp. is a precious and base metals exploration and development company focused on two primary objectives. The first of these objectives is the advancement of the La Cumbre oxide deposit. La Cumbre is located within the Company's 100% owned Batero–Quinchia Gold Project, which sits within Colombia's emerging and prolific Mid Cauca gold and copper belt. Batero intends to first target the near and at surface higher grade oxidized gold mineralization at the deposit. Batero's second objective is to pursue opportunities to acquire prospective high–grade, production–focused mineral properties in Colombia and Latin America. In pursuing both these objectives, Batero plans to leverage its secure treasury position, strong regional relationships, experienced management team, and long–term financial partners. Shares of the Vancouver–based company trade on the TSX–Venture Exchange under the symbol “BAT”.

FORWARD LOOKING STATEMENTS

Certain of the statements and information in this news release constitute “forward–looking statements” or “forward–looking information”. Any statements or information that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions or future events or performance (often, but not always, using words or phrases such as “expects”, “anticipates”, “believes”, “plans”, “estimates”, “intends”, “targets”, “goals”, “forecasts”, “objectives”, “potential” or variations thereof or stating that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved, or the negative of any of these terms and similar expressions) are not statements of historical fact and may be forward–looking statements or information.

Forward–looking statements or information may relate to, among other things: grades on the Batero–Quinchia Gold Project; scope of mineralization within the Batero–Quinchia Gold Project; results of exploration activities; receipt and/or timing of required permits and regulatory approvals; the Company's objectives with respect to advancement of the Batero–Quinchia Gold Project and acquisition of prospective high–grade, production–focused mineral properties in Colombia and Latin America; the sufficiency of the Company's capital to finance the Company's operations; and geological interpretations and potential mineral recovery processes.

The Company's actual results could differ materially from those anticipated in forward–looking statements and information. Forward–looking statements and information are subject to a variety of known and unknown risks, uncertainties and other factors that could cause actual events or results to differ from those reflected in the forward–looking statements or information, including, but not limited to, the following: uncertainty of whether there will ever be development or production at the Company's mineral exploration properties; geological, technical, drilling or processing problems; liabilities and risks, including environmental liabilities and risks, inherent in mineral exploration and development; fluctuations in currency exchange and interest rates; incorrect assessments of the value of acquisitions; unanticipated results of exploration activities; competition for, among other things, capital, undeveloped lands and skilled personnel; lack of availability of additional financing and/or joint venture partners; unpredictable weather conditions, as well as those other risk factors described under the heading “Financial Instruments and Other Risk Exposures” set forth in the Company's management's discussion and analysis.

The Company's forward–looking statements and information are based on the assumptions, beliefs, expectations and opinions of management as of the date of this news release, including, but not limited to, that the results of planned exploration activities are as anticipated, the price of metals, the anticipated cost of planned exploration activities, that general business and economic conditions will not change in a material adverse manner, that financing will be available if and when needed and on reasonable terms, and that third party contractors, equipment and supplies and governmental and other approvals required to conduct the Company's planned exploration activities will be available on reasonable terms and in a timely manner. Other than as required by applicable securities laws, the Company does not assume any obligation to update forward–looking statements or information in the event that circumstances or management's assumptions, beliefs, expectations or opinions should change, or there should occur or develop changes in any other events affecting such statements or information. For the reasons set forth above, investors should not place undue reliance on forward–looking statements and information.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Doubleview Capital Corp. (TSX-V: DBV) receives alleged notice of default on convertible debenture

VANCOUVER, BC—(Marketwired – August 16, 2017) – Doubleview Capital Corp. (“Doubleview”) (TSX VENTURE: DBV) announces it received a notice of an alleged event of default with respect to its convertible notes due August 1, 2018 (the “Notes”). The noteholders advise that they intend to accelerate the due date for the outstanding principal amount of the Notes and other amounts due under the Notes. Doubleview is currently reviewing the notice of default consulting its legal counsel regarding how to respond to the alleged notice of default.

About Doubleview Capital Corp.

Doubleview Capital Corp., a mineral resource exploration and development company, is based in Vancouver, British Columbia, Canada and is publicly traded on the TSX–Venture Exchange (TSX VENTURE: DBV) (OTC PINK: DBLVF) (FRANKFURT: 1D4). Doubleview identifies, acquires and finances precious and base metal exploration projects in North America, particularly in British Columbia, Canada. Doubleview increases shareholder value through acquisition and exploration of quality gold, copper and silver properties and the application of advanced state–of–the–art exploration methods. Doubleview's portfolio of strategic properties provides diversification and mitigates investment risk.

On behalf of the Board of Directors,
Farshad Shirvani, President & Chief Executive Officer

Forward–Looking Statements

Information set forth in this news release contains forward–looking statements that are based on assumptions as of the date of this news release. These statements reflect management's current estimates, beliefs, intentions and expectations. They are not guarantees of future performance. Doubleview cautions that all forward looking statements are inherently uncertain and that actual performance may be affected by a number of material factors, many of which are beyond Doubleview's control. Such factors include, among other things: risks and uncertainties relating to Doubleview's ability to implement its exploration program on the Hat Property, limited operating history and the need to comply with environmental and governmental regulations. Accordingly, actual and future events, conditions and results may differ materially from the estimates, beliefs, intentions and expectations expressed or implied in the forward looking information. Except as required under applicable securities legislation, Doubleview undertakes no obligation to publicly update or revise forward–looking information.

NEITHER TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

Cooley's Koji Fukumura Begins Term as 45th Chair of the American Bar Association Section of Litigation

NEW YORK, NY—(Marketwired – August 16, 2017) – Koji Fukumura, chair of Cooley's securities litigation practice and member of the firm's management committee, became the 45th chair of the American Bar Association Section of Litigation. The Section of Litigation is the ABA's largest section, with 50,000+ members and 40+ active committees. Fukumura was elevated from his one–year term as chair–elect to chair for the 2017–2018 bar year at the conclusion of last weekend's ABA Annual Meeting.

“Koji is a natural leader within Cooley and a dedicated and active member of the ABA,” said Michael Attanasio, chair of Cooley's global litigation department. “We are proud of his elevation and incredibly supportive of him as he carries on the section's mission of providing valuable resources for all practitioners, in particular the next generation of courtroom advocates.”

Fukumura has one of the most active securities defense practices in the US. He has 20+ years' experience in complex commercial litigation, including the defense of securities class actions, derivative suits, M&A–related class actions and government investigations. He also regularly conducts internal investigations for boards as well as their audit or special litigation committees.

“I am excited to serve our members and the profession as chair of the Section of Litigation,” said Fukumura. “I cannot recall a time in the last 50 years when it was more important to be a lawyer and protect the institutions and ideals that are fundamental to our democracy.”

The mission of the ABA Section of Litigation is to provide litigators of all practice areas the resources needed to become successful and experienced advocates. The section is dedicated to upholding the rule of law and to offering its members numerous opportunities for business networking and career advancement and a large portfolio of professional and business development products, including books, periodicals, CLEs and webinars.

About Cooley LLP

Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high–stakes litigation, where innovation meets the law.

Cooley has 900 lawyers across 12 offices in the United States, China and Europe.

Patients Are Not the #1 Target for Social Media & Other Digital Marketing Strategies, New Study Finds

RESEARCH TRIANGLE PARK, NC—(Marketwired – August 16, 2017) – A new study of pharmaceutical marketing teams found that the primary digital strategy priority is to educate and communicate with physicians, making communication with patients across digital platforms a secondary priority.

Industry data collected and analyzed by business intelligence firm, Cutting Edge Information, revealed that 80% of surveyed life science marketing teams consider healthcare physicians (HCPs) their primary target, with over 63% of surveyed teams using mobile health applications (mHealth) for physician detailing and physician education.

The study, Pharmaceutical Marketing: Reevaluate Digital Trends and Metrics for Social Media and Mobile Success, found that from the 40% of surveyed pharmaceutical marketing teams targeting patients, half (50%) of them use mobile initiatives for patient education.

“Digital marketing is a relatively new frontier for the life science industry,” said Natalie DeMasi, research team leader at Cutting Edge Information. “One of the biggest challenges in the digital marketing space is for teams to incorporate these new technologies in the restricted pharmaceutical environment.”

Data from the same study identified the second largest group (60%) targeted for digital marketing strategies as sales representatives, medical science liaisons (MSLs) and other field forces.

Cutting Edge Information's study, Pharmaceutical Marketing: Reevaluate Digital Trends and Metrics for Social Media and Mobile Success, available at https://www.cuttingedgeinfo.com/product/pharmaceutical–marketing/, explores the specific objectives, platforms and ROI metrics that life science teams employ in digital marketing. This report features analysis of exciting and potentially concerning up–and–coming trends in the digital marketing space.

This report is designed to help marketing executives:

  • Determine how to allocate your team's marketing and digital marketing budget
  • Identify key objectives and primary platforms used for social media and mHealth initiatives
  • Distinguish the most effective metrics and methods for evaluating digital marketing initiatives

For more information about pharmaceutical industry marketing, please visit https://www.cuttingedgeinfo.com/product–category/marketing/.

Image Available: http://www.marketwire.com/library/MwGo/2017/8/9/11G143964/Images/mw1bn449u8bnr11i7rnk4cjh1b4e2–4df367f1d9fba6299a983e72a0c36039.jpg
Image Available: http://www.marketwire.com/library/MwGo/2017/8/9/11G143964/Images/mw1bn448lg21lhk164l1jr24gmk22–a513ffbffadf962cbb3ee8d830d4cb07.jpg

Patients Are Not the #1 Target for Social Media & Other Digital Marketing Strategies, New Study Finds

RESEARCH TRIANGLE PARK, NC—(Marketwired – August 16, 2017) – A new study of pharmaceutical marketing teams found that the primary digital strategy priority is to educate and communicate with physicians, making communication with patients across digital platforms a secondary priority.

Industry data collected and analyzed by business intelligence firm, Cutting Edge Information, revealed that 80% of surveyed life science marketing teams consider healthcare physicians (HCPs) their primary target, with over 63% of surveyed teams using mobile health applications (mHealth) for physician detailing and physician education.

The study, Pharmaceutical Marketing: Reevaluate Digital Trends and Metrics for Social Media and Mobile Success, found that from the 40% of surveyed pharmaceutical marketing teams targeting patients, half (50%) of them use mobile initiatives for patient education.

“Digital marketing is a relatively new frontier for the life science industry,” said Natalie DeMasi, research team leader at Cutting Edge Information. “One of the biggest challenges in the digital marketing space is for teams to incorporate these new technologies in the restricted pharmaceutical environment.”

Data from the same study identified the second largest group (60%) targeted for digital marketing strategies as sales representatives, medical science liaisons (MSLs) and other field forces.

Cutting Edge Information's study, Pharmaceutical Marketing: Reevaluate Digital Trends and Metrics for Social Media and Mobile Success, available at https://www.cuttingedgeinfo.com/product/pharmaceutical–marketing/, explores the specific objectives, platforms and ROI metrics that life science teams employ in digital marketing. This report features analysis of exciting and potentially concerning up–and–coming trends in the digital marketing space.

This report is designed to help marketing executives:

  • Determine how to allocate your team's marketing and digital marketing budget
  • Identify key objectives and primary platforms used for social media and mHealth initiatives
  • Distinguish the most effective metrics and methods for evaluating digital marketing initiatives

For more information about pharmaceutical industry marketing, please visit https://www.cuttingedgeinfo.com/product–category/marketing/.

Image Available: http://www.marketwire.com/library/MwGo/2017/8/9/11G143964/Images/mw1bn449u8bnr11i7rnk4cjh1b4e2–4df367f1d9fba6299a983e72a0c36039.jpg
Image Available: http://www.marketwire.com/library/MwGo/2017/8/9/11G143964/Images/mw1bn448lg21lhk164l1jr24gmk22–a513ffbffadf962cbb3ee8d830d4cb07.jpg

UPDATE – Schuyler County Joins Growing List of New York Counties Against Opioids

WATKINS GLEN, NY—(Marketwired – August 16, 2017) – Schuyler County has become the latest New York State county to take action against the manufacturers and distributors of opioid pain killers.

The County Legislature voted Monday (August 14) to retain the firm of Napoli Shkolnik PLLC to file a lawsuit on their behalf. Schuyler County joins other New York Counties and numerous municipalities nationwide already represented by Napoli Shkolnik PLLC.

Napoli Shkolnik PLLC will work with Schuyler County Attorney Steven J. Getman, as special counsel, to bring an action against the manufacturers and distributors of prescription opiates for damages to the County arising out of the fraudulent and negligent marketing and distribution of opiates in and to the County.

“Over the past few years, despite its small population, Schuyler County has seen an uptick in opioid and heroin use and overdose,” Getman said. “To date, County officials have expended significant resources to help its residents battle opioid addiction and prevent further deaths. The lawsuit will seek to reimburse the County for its expenses related to the opioid crisis as well as provide the County with financial assistance to continue this battle.”

According to County Administrator Tim O'Hearn, the lawsuit will be filed at no risk to the County, as Napoli Shkolnik will work on contingency basis that will cover all costs associated with the lawsuit.

“By voting to go forward with litigation, the County Legislature hopes to lessen the burden to taxpayers and seeks to hold manufacturers and distributors responsible for their role in the opioid epidemic,” O'Hearn said.

“For many years the manufacturers and distributors of opioid pain medications have earned billions of dollars in profits flooding this Country with opioids,” says Napoli Shkolnik PLLC attorney Joseph L. Ciaccio. “These lawsuits seek to force those companies to help clean up the devastation caused by these pills.”

“These drug companies have poisoned our communities and polluted our children,” says Paul Napoli, of counsel for Napoli Shkolnik PLLC. Paul Napoli leads the charge with Hunter J. Shkolnik against drug companies nationwide.

“The painkiller overdose epidemic is a classic case of putting profits before people,” he said. “Many opioid manufacturers were so intent on selling as much product as possible that they either turned a blind eye towards, or intentionally buried, reports that these drugs were highly addictive and potentially deadly.”

Napoli added that “our door is open” to other New York municipalities who are also fed up with the overdose epidemic, and that Napoli Law has the firepower to go toe–to–toe with the big pharma lawyers.

Napoli has dedicated much of his career to mass tort litigation. He has fought on behalf of 9/11 injury victims at both the statehouse and the courthouse, and he and his team also took on the big energy companies which contaminated much of Long Island's drinking water supply with dangerously high levels of methyl tertiary butyl ether.